CLAIMS

1. A promoter of the synoviolin gene, comprising at least the nucleotide sequence of nucleotides 2120-2130 in the nucleotide sequence represented by SEQ ID: NO 1 or 2.

2. A promoter of the synoviolin gene, comprising any nucleotide sequence selected from a group consisting of at least the nucleotide sequences of the regions of nucleotides 1-2201, 969-2201, 1142-2201, 1699-2201, 1880-2201, 2002-2201, 2094-2201 and 2118-2201 in the nucleotide sequence represented by SEQ ID: NO 1 or 2.

3. A promoter of the synoviolin gene, comprising any nucleotide sequence selected from a group consisting of at least the nucleotide sequences of the regions of nucleotides No. 1-3043, 969-3043, 1142-3043, 1699-3043, 1880-3043, 2002-3043, 2094-3043 and 2118-3043 in the nucleotide sequence represented by SEQ ID: NO 1.

4. A promoter of the synoviolin gene, comprising any nucleotide sequence selected from a group consisting of at least the nucleotide sequences of the regions of nucleotides 1-3092, 969-3092, 1142-3092, 1699-3092, 1880-3092, 2002-3092, 2094-3092 and 2118-3092 in the nucleotide sequence represented by SEQ ID: NO 2.

5. The promoter of (a) or (b) below:

(a) A promoter of the synoviolin gene, comprising a nucleotide sequence having a deletion, substitution or insertion in some region of the nucleotide sequence of the promoter according to any one of Claims 1 to 4, and having promoter activity;

(b) A promoter of the synoviolin gene, comprising a nucleotide sequence which hybridizes under stringent conditions with a sequence complementary to the nucleotide sequence of the promoter according to any one of Claims 1 to 4, and having promoter activity.

6. A gene expression cassette comprising the promoter according to any one of Claims 1 to 5, a target gene for expression and a terminator.

7. A recombinant vector comprising the gene expression cassette according to Claim 6.

8. A transformant comprising the recombinant vector according to Claim 7.

9. A method for regulating transcription activity wherein the activity of the promoter according to any one of Claims 1 to 5 is inhibited or enhanced.

10. The method according to Claim 9, wherein inhibition or enhancement of the promoter activity inhibits or enhances the binding activity of a transcriptional factor.

11. The method according to Claim 10, wherein the binding site of the transcriptional factor is the Ets binding site.

12. The method according to Claim 10 or 11, wherein the transcriptional factor is any selected from the group consisting of GABPα, GABPβ, a complex of GABPα and GABPβ, Ets1, Pea3, Tel and Fli-1.